JP6192407B2 - Osmotic chemical administration system - Google Patents

Osmotic chemical administration system Download PDF

Info

Publication number
JP6192407B2
JP6192407B2 JP2013153493A JP2013153493A JP6192407B2 JP 6192407 B2 JP6192407 B2 JP 6192407B2 JP 2013153493 A JP2013153493 A JP 2013153493A JP 2013153493 A JP2013153493 A JP 2013153493A JP 6192407 B2 JP6192407 B2 JP 6192407B2
Authority
JP
Japan
Prior art keywords
wall
living body
body lumen
osmotic
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013153493A
Other languages
Japanese (ja)
Other versions
JP2015023904A (en
Inventor
洋平 谷川
洋平 谷川
靖展 伊賀
靖展 伊賀
真一 瀧本
真一 瀧本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olympus Corp
Original Assignee
Olympus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olympus Corp filed Critical Olympus Corp
Priority to JP2013153493A priority Critical patent/JP6192407B2/en
Publication of JP2015023904A publication Critical patent/JP2015023904A/en
Application granted granted Critical
Publication of JP6192407B2 publication Critical patent/JP6192407B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Endoscopes (AREA)

Description

本発明は、例えば、生体の管腔内壁に存在する患部に透明化液などの浸透性薬液を投与するために用いる浸透性薬液投与システムに関する。 The present invention is, for example, relates to osmotic drug solution administration system used to administer the permeability chemical such as transparency solution to the affected area which exists within the lumen wall of the living body.

ESD(Endoscopic submucosal dissection:内視鏡的粘膜下層剥離術)に代表される内視鏡治療や種々のカテーテル治療では、術中出血や術後出血のように臓器等の生体組織内に走行する血管や神経等を傷つける事故を回避することが従来からの課題とされている。   Endoscopic submucosal dissection (ESD) and other catheter treatments such as endoscopic submucosal dissection (endoscopic submucosal dissection) are blood vessels that run in living tissue such as organs, such as intraoperative or postoperative bleeding. It has been a conventional problem to avoid accidents that damage nerves and the like.

しかるに、生体組織内に染色剤、造影剤等の浸透性薬剤を浸透させることで、傷つけたくない部位を可視化しようとする試みがある。
従来、このような浸透性薬剤を内視鏡を用いて患部へ投与する場合、例えば、次の特許文献1〜4に記載のような噴霧装置を用いて、一定量の薬液を一度に噴霧することによって行なわれている。
However, there is an attempt to visualize a site that is not desired to be damaged by penetrating a penetrating agent such as a staining agent or a contrast agent into a living tissue.
Conventionally, when such an osmotic agent is administered to an affected area using an endoscope, for example, a spraying device as described in the following Patent Documents 1 to 4 is used to spray a certain amount of a chemical solution at a time. It is done by

特許文献1に記載の装置は、同時に送気、送液できる送気手段及び送液手段を有し、内視鏡の挿入部先端のチャンネル開口部から霧状に液体を噴出させる構成となっている。   The apparatus described in Patent Document 1 has an air supply means and a liquid supply means that can simultaneously supply and supply air, and ejects liquid in a mist form from the channel opening at the distal end of the insertion portion of the endoscope. Yes.

また、特許文献2に記載の装置は、送気圧力と送液圧力のいずれか一方の圧力切換に連動して他方の圧力を自動的に切換えて、内視鏡の挿入部先端に設けたノズルから気体と液体とを混合させて噴霧する構成となっている。   In addition, the device described in Patent Document 2 is a nozzle provided at the distal end of an insertion portion of an endoscope by automatically switching one of the air supply pressure and the liquid supply pressure in conjunction with the pressure switching. The gas and the liquid are mixed and sprayed.

また、特許文献3に記載の装置は、送液管先端に配置された回転案内溝を通過した液体が、液体回転室内で回転し、液体回転室の先端面中央に形成された噴出孔から前方に噴出する内視鏡用噴霧具において、液体回転室の先端側内壁面を、噴出孔側へ凸であって周辺より中央に近い側が軸線に対して垂直に近づくように面の向きが途中で変化した形状に形成することにより、十分に広い噴霧範囲を得る構成となっている。   Further, in the apparatus described in Patent Document 3, the liquid that has passed through the rotation guide groove disposed at the tip of the liquid feeding pipe rotates in the liquid rotating chamber, and forwards from an ejection hole formed in the center of the tip surface of the liquid rotating chamber. In the endoscope sprayer that is ejected in the direction of the surface, the inner wall surface on the tip side of the liquid rotation chamber is convex toward the ejection hole side and the side closer to the center than the periphery approaches the axis perpendicularly. By forming in a changed shape, a sufficiently wide spray range is obtained.

また、特許文献4に記載の装置は、送液管先端に配置された回転案内溝を通過した液体が、液体回転室内で回転し、液体回転室から拡散しながら放出される内視鏡用噴霧具において、液体回転室の前方を塞ぐと共に、外周壁部分にその全周にわたる環状の液体噴出口を形成することにより、管腔壁に対して液体を一様に噴霧する構成となっている。   In addition, the device described in Patent Document 4 is an endoscope spray in which liquid that has passed through a rotation guide groove disposed at the tip of a liquid feeding tube rotates in a liquid rotating chamber and is released while diffusing from the liquid rotating chamber. In the device, the front of the liquid rotating chamber is closed, and an annular liquid ejection port is formed on the outer peripheral wall portion so as to uniformly spray the liquid on the lumen wall.

特開2003−310540号公報JP 2003-310540 A 特開平09−294715号公報JP 09-294715 A 特開2001−137349号公報JP 2001-137349 A 特開2001−104490号公報JP 2001-104490 A

ところで、生体は部位ごとに種々の湿潤状態となっており、浸透性薬剤を適用することが所望される対象部位は、必ずしも生体管腔内において重力方向に存在するとは限らない。
このため、特許文献1〜4に記載の装置による重力方向に反する位置に存在する対象部位へ浸透性薬剤を噴霧する技術では、管腔内壁の表面に噴霧された薬液の液滴が重力方向に流れてしまう場合があり得、重力方向に反する方向に存在する対象部位に浸透性薬剤を安定的に留置させることが困難となる。
By the way, the living body is in various wet states for each part, and the target part where it is desired to apply the osmotic drug does not always exist in the direction of gravity in the living body lumen.
For this reason, in the technique of spraying a permeable drug onto a target site existing at a position opposite to the gravitational direction by the devices described in Patent Documents 1 to 4, the liquid droplets of the medicinal liquid sprayed on the surface of the lumen inner wall are in the gravitational direction. In some cases, it may flow, and it becomes difficult to stably place the osmotic agent in a target site that exists in a direction opposite to the direction of gravity.

また、一般に、浸透性薬剤の薬液は、生体組織に対しては有益なものではない。
このため、重力方向に反する方向にのみ患部が位置し、重力方向の生体組織が健康である場合、特許文献1〜4に記載の装置を用いて患部に噴霧した薬液が重力方向に流れると、適用したくない生体組織にまで薬液の影響を与える可能性がある。
In general, the medicinal solution of the osmotic drug is not useful for living tissue.
For this reason, when the affected part is located only in the direction opposite to the gravitational direction and the biological tissue in the gravitational direction is healthy, when the drug solution sprayed on the affected part using the devices described in Patent Documents 1 to 4 flows in the gravitational direction, There is a possibility that it may affect the biological tissue that is not desired to be applied.

しかも、特許文献1〜4に記載のような従来の噴霧装置は、所定量の薬液を対象部位に対し一度に噴霧する構成となっているので、必要な量の浸透性薬剤を、重力方向に反する方向に位置する対象部位の内部組織に浸透させ終えるまでの間に、対象部位の内部組織に浸透することなく、重力方向に流れて正常な生体組織に影響を与える場合もあり得る。このため、浸透性薬剤による効果を充分に得ながら、正常な生体組織への影響を考慮した投与技術が望まれる。   Moreover, since the conventional spraying devices as described in Patent Documents 1 to 4 are configured to spray a predetermined amount of a chemical solution onto the target site at a time, a necessary amount of osmotic agent is applied in the direction of gravity. There may be a case where normal biological tissue is affected by flowing in the direction of gravity without penetrating into the internal tissue of the target site until the internal tissue of the target site located in the opposite direction is completely penetrated. Therefore, an administration technique that takes into consideration the influence on normal living tissue while sufficiently obtaining the effect of the osmotic agent is desired.

重力方向に存在する患部に対し、薬液を安定的に留置させる従来技術としては、例えば、WO2009/031295号公報に記載のような薬剤を含有したポリマーでステントを被覆してなる、薬剤徐放性ステントがあるが、患部に投与後のステントの回収に手間がかかり、また、ステントが薬液を投与時の患部の観察の妨げとなり、薬液投与の効果を確認することが難しい等、薬液を投与した患部の診断・治療の妨げとなってしまう。   As a conventional technique for stably placing a drug solution on an affected part existing in the direction of gravity, for example, a sustained drug release property obtained by coating a stent with a polymer containing a drug as described in WO2009 / 031295 Although there is a stent, it took time to collect the stent after administration to the affected area, and the stent interfered with observation of the affected area during administration of the drug solution, and it was difficult to confirm the effect of the drug solution administration. This will interfere with the diagnosis and treatment of the affected area.

また、例えば、特開2008−188212号公報に記載のようなバルーンを膨張させて、薬剤保持部を所望の部位に接触して薬液を塗布するものもあるが、バルーンを膨張させて患部に接触した状態で薬液を投与する構成では、バルーンが薬液を投与時の患部の観察の妨げとなり、薬液投与の効果を確認することが難しい。   In addition, for example, there is a balloon that is inflated as described in Japanese Patent Application Laid-Open No. 2008-188212, and a drug holding part is brought into contact with a desired site to apply a chemical solution. In the configuration in which the drug solution is administered in such a state, it is difficult to confirm the effect of the drug solution administration because the balloon hinders observation of the affected area when the drug solution is administered.

本発明は、このような従来の問題点に鑑みてなされたものであり、生体への負担及び作業負担を軽減し、薬液のロスを極力省くことができ、重力に反する位置に存在する投与対象部位に対しても薬液を安定的に留置させた状態で、最適な量を調整することが可能で、しかも投与部位の視野を邪魔せず、薬液の投与効果を確認しながら投与することが可能な浸透性薬液投与システムを提供することを目的としている。 The present invention has been made in view of such conventional problems, and can reduce the burden on the living body and the work load, can reduce the loss of the drug solution as much as possible, and can be administered at a position against gravity. It is possible to adjust the optimal amount in a state where the drug solution is stably placed at the site, and it is possible to administer the drug solution while checking the effect of the drug solution without disturbing the visual field of the administration site and its object is to provide a Do osmotic drug solution administration system.

上記目的を達成するため、本発明者らは、近年、光散乱を抑制することで光の生体透過性を高めるために開発されつつある透明化液を上記のような医療用途に使用することを想定した。つまり、ダメージを与えたくない対象の周囲に存在する生体組織をできるだけ透明化することで、対象の視認性(透見性)を高めることが可能な投与について検討した。透明化液の組成の一例としては、尿素にグリセロールと界面活性剤を加えた水溶性の溶液であって、生体組織に投与することにより生体組織内に浸透し、浸透した部位をゼリー状に物理化学的変化をもたらしながら皮膚等の組織内に含まれる色素成分を透明化させる。透明化液としては、他にもポリエチレングリコールやグルコースのような組成を使用する場合がある。これら透明化液は、一般に無色透明であることと生体組織への物理化学的変化をもたらす性質等から、組成ごとに多様な物性を有することが多く、浸透具合を確認するのが特に困難である溶液といえる。なお、透明化液を用いて透明化された部位は、生理食塩水等を投与することによって、再び元の不透明な状態に戻すことができる。   In order to achieve the above-mentioned object, the present inventors have recently used a clearing solution that has been developed to enhance the biological permeability of light by suppressing light scattering for the medical use as described above. Assumed. That is, the administration which can improve the visibility (see-through property) of the object by making the living tissue existing around the object which does not want to be damaged as transparent as possible was examined. An example of the composition of the clearing solution is a water-soluble solution in which glycerol and a surfactant are added to urea, and it penetrates into the living tissue when administered to the living tissue, and the permeated site is physically converted into a jelly form. The pigment component contained in tissues such as skin is made transparent while causing a chemical change. There are other cases where a composition such as polyethylene glycol or glucose is used as the clearing solution. These clearing solutions generally have a variety of physical properties for each composition because of their colorless and transparent properties and the properties that cause physicochemical changes to living tissues, and it is particularly difficult to confirm the degree of penetration. A solution. In addition, the site | part clarified using the clarification liquid can be returned to the original opaque state again by administering physiological saline etc.

かかる透明化液を用いて術中出血や術後出血のリスクを軽減させるためには、術前又は術後に透明化液を患部へ投与し、血管透見能を向上させることが望まれる。
ところで、この透明化液は、投与した生体組織内へ充分な深さまで浸透してはじめてその効果を発揮する。そのため、透明化液を投与してから透明化効果が得られるまでには一定のタイムラグが存在する。このため、本発明は、手術等に透明化液を利用する場合、予め、透明化液を患部の内部組織に浸透させておくことも可能なシステムも提供する。本発明において、特に実施形態等で明示しない限り、浸透性薬剤とは透明化液を含む広義の薬剤をいう。
In order to reduce the risk of intraoperative or postoperative bleeding using such a clearing solution, it is desired to administer the clearing solution to the affected area before or after the operation to improve the blood vessel see-through ability.
By the way, this clearing solution exhibits its effect only when it penetrates to a sufficient depth into the administered biological tissue. Therefore, there is a certain time lag between the administration of the clearing solution and the obtaining of the clearing effect. Therefore, the present invention is, when using a transparent liquid to a surgical or the like, in advance, also provides also possible systems that allowed to penetrate the transparent liquid inside the tissue of the affected area. In the present invention, unless otherwise specified in the embodiment or the like, the osmotic drug refers to a broadly defined drug including a clearing solution.

本発明による浸透性薬液投与システムは、内視鏡を用いて浸透性薬液を生体管腔内壁へ投与する浸透性薬液投与システムであって、前記内視鏡先端部の側方から前記浸透性薬液を前記生体管腔内壁の表面へ噴霧可能に構成された薬液噴霧部と、前記薬液噴霧部により前記生体管腔内壁の表面へ噴霧された前記浸透性薬液が該生体管腔内壁の内部組織へ浸透する度合いを検出する浸透度合い検出部を有し、前記薬液噴霧部が前記浸透性薬液を前記生体管腔内壁の表面へ噴霧する第1の工程と、前記第1の工程の後に前記浸透度合い検出部により検出された前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達するまでの間、前記薬液噴霧部による前記浸透性薬液の前記生体管腔内壁の表面への噴霧を待機させる第2の工程とを交互に繰り返し、前記生体管腔内壁に対し所定量の前記浸透性薬液を複数回に分けて断続的に投与するようにしたことを特徴としている。   An osmotic drug solution administration system according to the present invention is an osmotic drug solution administration system that administers an osmotic drug solution to an inner wall of a living body lumen using an endoscope, and the osmotic drug solution from the side of the distal end portion of the endoscope. To a surface of the inner wall of the living body lumen, and a medicinal solution spraying section configured to be sprayable onto the surface of the inner wall of the living body lumen, and the osmotic drug solution sprayed onto the surface of the inner wall of the living body lumen to the inner tissue of the inner wall of the living body lumen A first step in which a penetrating degree detecting unit for detecting a penetrating degree is detected, and the medicinal solution spraying section sprays the penetrating medicinal solution on the surface of the inner wall of the living body lumen; and the penetrating degree after the first step. Until the degree of penetration of the osmotic drug solution detected by the detection unit into the internal tissue of the inner wall of the biological lumen reaches a predetermined level, the inner wall of the biological lumen of the osmotic drug solution by the drug solution spraying unit Wait for spraying on the surface of Alternately repeating the second step, it is characterized in that so as to administer the permeable chemical liquid of a predetermined amount relative to the body lumen wall divided by intermittently several times.

また、本発明の浸透性薬液投与システムにおいては、さらに、前記浸透度合い検出部により検出された前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達したときに、前記薬液噴霧部が前記浸透性薬液を前記生体管腔内壁の表面へ噴霧するように、前記薬液噴霧部の作動を制御する噴霧作動制御部を有するのが好ましい。   In the osmotic solution administration system of the present invention, when the penetration of the osmotic solution detected by the penetration level detection unit into the internal tissue of the inner wall of the living body lumen reaches a predetermined level. In addition, it is preferable to have a spray operation control unit that controls the operation of the chemical solution spray unit so that the chemical solution spray unit sprays the osmotic chemical solution onto the surface of the inner wall of the living body lumen.

また、本発明の浸透性薬液投与システムにおいては、さらに、前記浸透度合い検出部により検出された前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達したときに、前記薬液噴霧部による前記浸透性薬液の前記生体管腔内壁の表面への噴霧を指示する噴霧指示部を有するのが好ましい。   In the osmotic solution administration system of the present invention, when the penetration of the osmotic solution detected by the penetration level detection unit into the internal tissue of the inner wall of the living body lumen reaches a predetermined level. In addition, it is preferable to have a spray instructing unit that instructs spraying of the osmotic chemical solution onto the surface of the inner wall of the living body lumen by the chemical solution spraying unit.

また、本発明の浸透性薬液投与システムにおいては、前記浸透度合い検出部が、光ファイバを用いた干渉計からなるのが好ましい。   In the osmotic chemical solution administration system of the present invention, it is preferable that the penetration degree detection unit is an interferometer using an optical fiber.

また、本発明の浸透性薬液投与システムにおいては、前記浸透度合い検出部が、前記内視鏡の観察光学系を介して得られた前記生体管腔内壁の表面の画像を撮像する撮像部と、前記撮像部が撮像した前記生体管腔内壁の表面の画像から、該画像に写っている前記浸透性薬液の液滴の輪郭形状を抽出する画像処理部と、前記画像処理部で抽出された前記浸透性薬液の液滴の輪郭形状の鮮明度を検出する鮮明度検出部を有してなり、前記鮮明度検出部により検出された前記鮮明度が、前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いであるのが好ましい。   Further, in the osmotic drug solution administration system of the present invention, the penetration degree detection unit is configured to capture an image of the surface of the inner wall of the living body lumen obtained through the observation optical system of the endoscope; From the image of the surface of the inner wall of the living body lumen imaged by the imaging unit, an image processing unit that extracts a contour shape of the droplet of the osmotic drug solution that is reflected in the image; and the image processing unit that is extracted by the image processing unit A sharpness detecting unit that detects the sharpness of the contour shape of the droplet of the osmotic chemical solution, and the sharpness detected by the sharpness detection unit is the inner wall of the living body lumen of the osmotic chemical solution The degree of penetration into the internal tissue is preferred.

また、本発明の浸透性薬液投与システムにおいては、さらに、前記内視鏡の観察光学系を介して得られた前記生体管腔内壁の画像から前記生体管腔内壁の内部組織の状態変化を検出する状態変化検出部を有し、前記噴霧作動制御部は、前記状態変化検出部により検出される前記生体管腔内壁の内部組織の状態変化が所定状態に到達したときに、前記薬液噴霧部による前記浸透性薬液の前記生体管腔内壁の表面への噴霧を終了させるように、前記薬液噴霧部の作動を制御するのが好ましい。   In the osmotic drug solution administration system of the present invention, a change in the state of the internal tissue of the inner wall of the living body lumen is further detected from an image of the inner wall of the living body lumen obtained through the observation optical system of the endoscope. A state change detection unit configured to detect the state of the internal tissue of the inner wall of the living body lumen detected by the state change detection unit when the state change of the internal tissue reaches a predetermined state. It is preferable to control the operation of the chemical solution spraying unit so as to finish spraying the osmotic chemical solution onto the surface of the inner wall of the living body lumen.

本発明によれば、生体への負担及び作業負担を軽減し、薬液のロスを極力省くことができ、重力に反する位置に存在する投与対象部位に対しても薬液を安定的に留置させた状態で、最適な量を調整することが可能で、しかも投与部位の視野を邪魔せず、薬液の投与効果を確認しながら投与することが可能な浸透性薬液投与システムが得られる。 According to the present invention, it is possible to reduce the burden on the living body and the work load, reduce the loss of the drug solution as much as possible, and stably place the drug solution on the administration target site that exists at a position against gravity. in, it is possible to adjust the optimum amount, moreover without disturbing the view of the injection site, osmotic drug solution administered system that can be administered is obtained while confirming the effect of the administration of the drug solution.

本発明の第1実施形態にかかる浸透性薬液投与システムの概略構成を示す説明図で、(a)は模式図、(b)は要部構成を示すブロック図である。BRIEF DESCRIPTION OF THE DRAWINGS It is explanatory drawing which shows schematic structure of the osmotic chemical | medical solution administration system concerning 1st Embodiment of this invention, (a) is a schematic diagram, (b) is a block diagram which shows the principal part structure. 図1の浸透性薬液投与システムにおける浸透度合い検出部の一構成例を模式的に示す説明図である。It is explanatory drawing which shows typically the example of 1 structure of the osmosis | permeation degree detection part in the osmotic chemical | medical solution administration system of FIG. 図1の浸透性薬液投与システムにおける浸透度合い検出部の他の構成例を模式的に示す説明図である。It is explanatory drawing which shows typically the other structural example of the penetration degree detection part in the osmotic chemical | medical solution administration system of FIG. 図1の浸透性薬液投与システムにおける浸透性薬液を生体管腔内壁に投与し終えるまでの手順を示すフローチャートである。It is a flowchart which shows the procedure until it completes administering the osmotic chemical | medical solution to the living body lumen inner wall in the osmotic chemical | medical agent administration system of FIG. 図1の浸透性薬液投与システムにおいて浸透性薬液を生体管腔内壁に投与し終えるまでの投与のタイミングチャートを示す説明図である。It is explanatory drawing which shows the timing chart of administration until it completes administering an osmotic chemical | medical solution to a biological lumen inner wall in the osmotic chemical | medical solution administration system of FIG.

実施形態の説明に先立ち、本発明の作用効果について説明する。
本発明の浸透性薬液投与システムは、内視鏡先端部の側方から浸透性薬液を生体管腔内壁の表面へ噴霧する薬液噴霧部と、薬液噴霧部から生体管腔内壁の表面へ噴霧された浸透性薬液の生体管腔内壁の内部組織への浸透する度合いを検出する浸透度合い検出部を有し、薬液噴霧部が浸透性薬液を生体管腔内壁の表面へ噴霧する第1の工程と、第1の工程の後に浸透度合い検出部により検出された浸透性薬液の生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達するまでの間、薬液噴霧部による浸透性薬液の生体管腔内壁の表面への噴霧を待機させる第2の工程とを交互に繰り返し、生体管腔内壁に対し所定量の浸透性薬液を複数回に分けて断続的に投与する。
Prior to the description of the embodiment, the function and effect of the present invention will be described.
The osmotic drug solution administration system of the present invention is sprayed from the side of the endoscope tip part to the surface of the inner wall of the living body lumen from the side of the endoscope tip part, and sprayed from the drug solution spraying part to the surface of the inner wall of the body lumen. And a first step of spraying the osmotic chemical liquid onto the surface of the inner wall of the living body lumen, the penetrating degree detecting unit detecting the degree of penetration of the osmotic drug solution into the inner tissue of the inner wall of the living body lumen. Until the degree of penetration of the osmotic drug solution detected by the penetration level detection unit after the first step into the internal tissue of the inner wall of the living body lumen reaches a predetermined level, The second step of waiting for spraying on the surface of the inner wall of the living body lumen is alternately repeated, and a predetermined amount of osmotic drug solution is intermittently administered to the inner wall of the living body lumen in a plurality of times.

本発明の浸透性薬液投与システムのようにすれば、生体管腔内壁に対する十分な効果を得るために必要な全投与量の浸透性薬液を複数回に分けて少量ずつ霧状の液滴にして供給することができるので、浸透性薬液の液滴が生体管腔内壁の表面に留まり易くなる。そして、生体管腔内壁における浸透性薬液の投与対象部位が重力方向に反する位置に位置していても、噴霧した浸透性薬液の液滴が重力方向に流れることなく、安定的に投与することができる。   According to the osmotic drug administration system of the present invention, the osmotic drug solution of the total dose necessary for obtaining a sufficient effect on the inner wall of the living body lumen is divided into a plurality of times to form mist-like droplets. Since it can supply, the droplet of a permeable chemical | medical solution becomes easy to remain on the surface of a biological lumen inner wall. And even if the osmotic drug solution administration target site on the inner wall of the living body lumen is located at a position opposite to the gravity direction, the sprayed droplets of the osmotic drug solution can be stably administered without flowing in the gravity direction. it can.

また、本発明の浸透性薬液投与システムのようにすれば、浸透性薬液を噴霧後に一定時間、噴霧を待機させることによって、生体管腔内壁において重力方向に反する位置に位置する投与対象部位に噴霧した浸透性薬液の液滴が大きくなって重力方向に流れることを防ぎ、浸透性薬液を生体管腔内壁の内部組織に浸透させることができる。   Further, according to the osmotic drug solution administration system of the present invention, spraying is applied to the administration target site located at a position opposite to the gravity direction on the inner wall of the living body lumen by allowing the osmotic drug solution to wait for a predetermined time after spraying. It is possible to prevent the osmotic chemical liquid droplets from becoming large and flowing in the direction of gravity, and to allow the osmotic chemical liquid to permeate the internal tissue of the inner wall of the living body lumen.

そして、本発明の浸透性薬液投与システムのようにすれば、生体管腔内壁において重力方向に反する位置に位置する投与対象部位に噴霧した浸透性薬液の液滴が重力方向に流れることがない結果、生体管腔内壁に対する十分な効果を得るために必要最小限となる最適量の浸透性薬液を供給して、浸透性薬液のロスを抑えることができるとともに、健康であって浸透性薬液の投与が不必要な部位へ浸透性薬液が投与されることを無くすことができ、健康な生体組織への負担を与えずに済む。   According to the osmotic drug solution administration system of the present invention, the droplets of the osmotic drug sprayed on the administration target site located at the position opposite to the gravity direction on the inner wall of the living body lumen do not flow in the gravity direction. The optimal amount of osmotic chemical solution that is necessary to obtain a sufficient effect on the inner wall of a living body lumen can be supplied to suppress the loss of the osmotic chemical solution, and the administration of the osmotic chemical solution is healthy However, it is possible to eliminate the administration of the osmotic chemical solution to an unnecessary site, and it is not necessary to give a burden to healthy living tissue.

また、本発明の浸透性薬液投与システムのように、浸透性薬液の投与を内視鏡先端部の側方から浸透性薬液を生体管腔内壁の表面へ噴霧する薬液噴霧部を介して行えば、例えば、薬液を徐放するためのバルーンを用いる構成や、WO2009/031295号公報に記載の薬剤徐放性ステントのように、薬液の投与部位の視野を妨げない。このため、生体管腔内壁における投与部位での効果を確認しながら浸透性薬液を投与することができる。   In addition, as in the osmotic drug solution administration system of the present invention, if the osmotic drug solution is administered from the side of the endoscope tip part through the drug solution spraying part that sprays the osmotic drug solution on the surface of the inner wall of the body lumen, For example, the field of view of the administration site of the drug solution is not obstructed as in the configuration using a balloon for sustained release of the drug solution and the drug sustained release stent described in WO2009 / 031295. For this reason, it is possible to administer the osmotic drug solution while confirming the effect at the administration site on the inner wall of the body lumen.

従って、本発明の浸透性薬液投与システムによれば、生体への負担及び作業負担を軽減し、薬液のロスを極力省くことができ、重力に反する位置に存在する投与対象部位に対しても薬液を安定的に留置させた状態で、最適な量を調整することが可能で、しかも投与部位の視野を邪魔せず、薬液の投与効果を確認しながら投与することが可能な浸透性薬液投与システムが得られる。   Therefore, according to the osmotic chemical solution administration system of the present invention, the burden on the living body and the work load can be reduced, the loss of the chemical solution can be reduced as much as possible, and the chemical solution can be applied to the administration target site that exists at a position against gravity. Penetrating drug solution administration system that can adjust the optimal amount in a state where it is stably placed, and can be administered while confirming the effect of the drug solution without disturbing the visual field of the administration site Is obtained.

ところで、生体管腔内壁の表面は体液で覆われているため、薬液を噴霧しても体液と混じり易い。このため、操作者が生体管腔内壁に噴霧した浸透性薬液の生体管腔内壁の内部組織への浸透の度合いを内視鏡の観察光学系を介して確認することは容易ではなく、操作者の作業負担が増加する。
しかるに、本発明の浸透性薬液投与システムにおいて、浸透度合い検出部により検出された浸透性薬液の生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達したときに、薬液噴霧部が浸透性薬液を生体管腔内壁の表面へ噴霧するように、薬液噴霧部の作動を制御する噴霧作動制御部を有すれば、薬液噴霧部を介して浸透性薬液を噴霧するのに最適なタイミングを簡単に取得して、最適なタイミングで浸透性薬液を自動的に噴霧させることができるので、操作者による噴霧指示の確認や薬液噴霧部の作動を手動で操作する手間を省いて、操作者の作業負担を軽減することができる。
By the way, since the surface of the inner wall of the living body lumen is covered with the body fluid, it is easy to mix with the body fluid even if the drug solution is sprayed. For this reason, it is not easy for the operator to confirm the degree of penetration of the osmotic chemical solution sprayed on the inner wall of the living body lumen into the internal tissue of the inner wall of the living body lumen through the observation optical system of the endoscope. Work burden increases.
However, in the osmotic drug solution administration system of the present invention, when the degree of penetration of the osmotic drug solution detected by the penetration level detection unit into the internal tissue of the inner wall of the body lumen reaches a predetermined level, the drug solution spraying unit If there is a spray operation control unit that controls the operation of the chemical solution spraying part to spray the osmotic chemical solution on the surface of the inner wall of the living body lumen, the optimal timing for spraying the osmotic chemical solution through the chemical solution spraying part Can be easily obtained and the osmotic chemical solution can be automatically sprayed at the optimal timing, eliminating the need for the operator to confirm the spray instruction and manually operating the chemical spray unit. Work burden can be reduced.

また、本発明の浸透性薬液投与システムにおいて、さらに、浸透度合い検出部により検出された浸透性薬液の生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達したときに、薬液噴霧部による浸透性薬液の生体管腔内壁の表面への噴霧を指示する噴霧指示部を有すれば、操作者による噴霧指示の確認の手間を省いて、操作者の作業負担を軽減することができる。   Further, in the osmotic drug administration system of the present invention, when the degree of penetration of the osmotic drug solution detected by the penetration degree detection unit into the internal tissue of the inner wall of the body lumen reaches a predetermined level, the drug spray If there is a spray instruction unit for instructing spraying of the osmotic chemical solution on the surface of the inner wall of the body lumen by the unit, it is possible to reduce the burden on the operator by eliminating the trouble of confirming the spray instruction by the operator. .

また、本発明の浸透性薬液投与システムにおいて、浸透度合い検出部を、光ファイバを用いた干渉計で構成すれば、噴霧した浸透性薬液の液滴が生体管腔内壁の表面の体液と混ざって、観察画像からは浸透性薬液が生体管腔内壁の内部組織への浸透の度合いが判別しにくくなるような場合であっても、浸透性薬液と生体管腔内壁の表面及び生体管腔内壁の表面に付着する体液との夫々の屈折率の差異に基づく信号光の光路長の変化を、信号光と参照光との合波された光の強度の違いとして区別することができるため、浸透性薬液が生体管腔内壁の内部組織へ浸透する度合いを正確に検出することができる。   Further, in the osmotic drug solution administration system of the present invention, when the penetration degree detection unit is configured by an interferometer using an optical fiber, the sprayed droplets of the osmotic drug solution are mixed with the body fluid on the surface of the inner wall of the living body lumen. Even if it is difficult to determine the degree of penetration of the osmotic chemical from the observation image into the internal tissue of the inner wall of the living body lumen, the surface of the inner wall of the living body lumen and the inner wall of the living body lumen The change in the optical path length of the signal light based on the difference in refractive index from the body fluid adhering to the surface can be distinguished as the difference in intensity of the combined light of the signal light and the reference light. The degree of penetration of the drug solution into the internal tissue of the inner wall of the living body lumen can be accurately detected.

また、本発明の浸透性薬液投与システムにおいて、浸透度合い検出部を、内視鏡の観察光学系を介して得られた生体管腔内壁の表面の画像を撮像する撮像部と、撮像部が撮像した生体管腔内壁の表面の画像における噴霧された浸透性薬液の液滴の輪郭形状を抽出する画像処理部と、画像処理部で抽出された浸透性薬液の液滴の輪郭形状の鮮明度を検出する鮮明度検出部を有して構成すれば、内視鏡先端部に浸透度合いを検出するための部材を新たに設ける必要がない。このため、内視鏡先端部を極力小さく抑えることができ、径の小さな生体管腔内壁に対しても浸透性薬液の浸透の度合いを検出することができるようになる。   Further, in the osmotic drug administration system of the present invention, the penetration degree detection unit is configured to capture an image of the surface of the inner wall of the living body lumen obtained through the observation optical system of the endoscope, and the imaging unit captures the image. The image processing unit for extracting the contour shape of the sprayed penetrating chemical liquid droplet in the surface image of the inner wall of the living body lumen, and the sharpness of the contour shape of the penetrating chemical liquid droplet extracted by the image processing unit. If it is configured to have a sharpness detection unit for detection, it is not necessary to newly provide a member for detecting the penetration level at the distal end portion of the endoscope. Therefore, the distal end portion of the endoscope can be suppressed as small as possible, and the degree of penetration of the osmotic drug solution can be detected even with respect to the inner wall of the living body lumen having a small diameter.

また、本発明の浸透性薬液投与システムにおいて、さらに、内視鏡の観察光学系を介して得られた生体管腔内壁の画像から生体管腔内壁の内部組織の状態変化を検出する状態変化検出部を有し、噴霧作動制御部は、状態変化検出部により検出される生体管腔内壁の内部組織の状態変化が所定状態に到達したときに、薬液噴霧部による浸透性薬液の生体管腔内壁の表面への噴霧を終了させるように、薬液噴霧部の作動を制御するように構成すれば、操作者の作業負担を減らしながら、過剰投与を防止して最適な量の浸透性薬液を生体管腔内壁に投与することができる。   Further, in the osmotic drug administration system of the present invention, the state change detection further detects the state change of the internal tissue of the inner wall of the living body lumen from the image of the inner wall of the living body lumen obtained through the observation optical system of the endoscope And the spray operation control unit is configured so that when the state change of the internal tissue of the inner wall of the living body lumen detected by the state change detecting unit reaches a predetermined state, the inner wall of the living body lumen of the permeable medicinal solution by the medicinal solution spraying unit If it is configured to control the operation of the chemical spraying unit so that the spraying on the surface of the liquid is terminated, it reduces the work burden on the operator and prevents overdosing and supplies the optimal amount of osmotic chemical solution to the biological tube. It can be administered to the lumen wall.

以下、本発明の実施形態について、図面を用いて説明する。
第1実施形態
図1は本発明の第1実施形態にかかる浸透性薬液投与システムの概略構成を示す説明図で、(a)は模式図、(b)は要部構成を示すブロック図である。図2は図1の浸透性薬液投与システムにおける浸透度合い検出部の一構成例を模式的に示す説明図である。図3は図1の浸透性薬液投与システムにおける浸透度合い検出部の他の構成例を模式的に示す説明図である。図4は図1の浸透性薬液投与システムにおいて浸透性薬液を生体管腔内壁に投与し終えるまでの手順を示すフローチャートである。図5は図1の浸透性薬液投与システムにおける浸透性薬液を生体管腔内壁に投与し終えるまでの投与のタイミングチャートを示す説明図である。
Hereinafter, embodiments of the present invention will be described with reference to the drawings.
First Embodiment FIG. 1 is an explanatory view showing a schematic configuration of an osmotic chemical solution administration system according to a first embodiment of the present invention, wherein (a) is a schematic diagram, and (b) is a block diagram showing a main part configuration. . FIG. 2 is an explanatory view schematically showing a configuration example of a penetration degree detecting unit in the osmotic chemical solution administration system of FIG. FIG. 3 is an explanatory diagram schematically showing another configuration example of the penetration degree detection unit in the osmotic chemical solution administration system of FIG. FIG. 4 is a flowchart showing a procedure until administration of the osmotic drug solution to the inner wall of the living body lumen is completed in the osmotic drug solution administration system of FIG. FIG. 5 is an explanatory diagram showing a timing chart of administration until the osmotic drug solution in the osmotic drug solution administration system of FIG.

本実施形態の浸透性薬液投与システムは、図1に示すように、薬液噴霧部1と、浸透度合い検出部2を有している。なお、図中、3は噴霧作動制御部、4は観察光学系、5は状態変化検出部、10は内視鏡先端部、20は浸透性薬液、30は生体管腔内壁、30aは生体管腔内壁の一部に存在する患部である。ここでは、患部30aは重力に反する方向に位置しているものとする。   As shown in FIG. 1, the osmotic chemical solution administration system of the present embodiment includes a chemical solution spray unit 1 and a penetration level detection unit 2. In the figure, 3 is a spray operation control unit, 4 is an observation optical system, 5 is a state change detection unit, 10 is a distal end portion of an endoscope, 20 is an osmotic chemical solution, 30 is a biological lumen inner wall, and 30a is a biological tube. This is a diseased part existing in a part of the inner cavity wall. Here, it is assumed that the affected part 30a is located in a direction against gravity.

薬液噴霧部1は、内視鏡の鉗子チャネルから挿入された透明化液の噴霧デバイスで構成されている。そして、薬液噴霧部1は、内視鏡先端部10から延びている棒状の可撓性部材11の内部に設けられた薬液の供給路1aと、供給路1aに連通し、可撓性部材11の側方に環状に複数設けられた供給口1bと、図示しない内視鏡本体部に設けられていて供給路1aに連通する図示しないポンプ等の薬液供給手段を備えており、供給口1aを介して内視鏡先端部10の側方から浸透性薬液20を生体管腔内壁30の表面へ噴霧することができるように構成されている。   The medicinal solution spraying section 1 is composed of a clearing solution spraying device inserted from a forceps channel of an endoscope. The medicinal solution spray unit 1 communicates with the medicinal solution supply path 1 a provided inside the rod-shaped flexible member 11 extending from the endoscope distal end 10 and the supply path 1 a, and the flexible member 11. A plurality of supply ports 1b provided in a ring shape on the side of the endoscope, and a chemical solution supply means such as a pump (not shown) provided in the endoscope main body (not shown) and communicating with the supply path 1a are provided. Thus, the osmotic chemical solution 20 can be sprayed onto the surface of the inner wall 30 of the living body lumen from the side of the endoscope distal end portion 10.

浸透度合い検出部2は、薬液噴霧部1から生体管腔内壁30の表面へ噴霧された浸透性薬液20の生体管腔内壁30の内部組織への浸透度合いを検出する。
詳しくは、浸透度合い検出部2は、例えば、図2に示すような、光ファイバを用いた干渉計2aで構成されている。
光ファイバを用いた干渉計2aは、光源部2a1と、ファイバカプラ2a2と、参照光反射系2a3と、プローブ部2a4と、光検出部2a5を有している。
光源部2a1は、低コヒーレンス光を発するように構成されている。
ファイバカプラ2a2は、シングルモードファイバ2a6を介して光源部2a1と、シングルモードファイバ2a7を介して参照光反射系2a3と、シングルモードファイバ2a8を介してプロープ部2a4と、シングルモードファイバ2a9を介して光検出部2a5と、夫々接続されている。そして、ファイバカプラ2a2は、光源部2a1からの光を信号光L1と参照光L2とに分岐するとともに、生体管腔内壁30で反射した信号光L1と参照光反射系2a3からの参照光L2とを合波して光検出部2a5に導く。
参照光反射系2a3は、シングルモードファイバ2a7の先端にレンズ2a31と、ミラー2a32と、ミラー駆動部2a33を有し、ミラー駆動部2a33を介してミラー2a32を光軸方向に移動させることで参照光L2の光路長を変えることができるようになっている。
プローブ部2a4は、シングルモードファイバ2a8の先端にレンズ2a41を有し、レンズ2a41を経てコリメートされた信号光L1を生体管腔内壁30に照射するとともに、生体管腔内壁30で反射した光をシングルモードファイバ2a8に導く。
光検出部2a5は、信号光L1と参照光L2とが合波された光の強度を検出する。
The penetration degree detection unit 2 detects the degree of penetration of the permeable chemical solution 20 sprayed from the chemical solution spray unit 1 onto the surface of the inner wall 30 of the living body lumen into the internal tissue of the inner wall 30 of the living body lumen.
Specifically, the penetration degree detection unit 2 includes, for example, an interferometer 2a using an optical fiber as shown in FIG.
The interferometer 2a using an optical fiber includes a light source unit 2a1, a fiber coupler 2a2, a reference light reflection system 2a3, a probe unit 2a4, and a light detection unit 2a5.
The light source unit 2a1 is configured to emit low coherence light.
The fiber coupler 2a2 includes a light source unit 2a1 through a single mode fiber 2a6, a reference light reflection system 2a3 through a single mode fiber 2a7, a probe unit 2a4 through a single mode fiber 2a8, and a single mode fiber 2a9. Each is connected to the light detection unit 2a5. The fiber coupler 2a2 branches the light from the light source unit 2a1 into the signal light L1 and the reference light L2, and the signal light L1 reflected by the living body lumen inner wall 30 and the reference light L2 from the reference light reflection system 2a3. Are combined and guided to the light detector 2a5.
Reference light reflection system 2a3 is moved lens 2a3 1 to the tip of the single mode fiber 2A7, a mirror 2a3 2, it has a mirror driving unit 2a3 3, the mirror 2a3 2 in the optical axis direction via the mirror drive unit 2a3 3 By doing so, the optical path length of the reference light L2 can be changed.
Probe unit 2a4 includes a lens 2a4 1 to the tip of the single mode fiber 2A8, the signal light L1 collimated through a lens 2a4 1 irradiates the body lumen wall 30, the light reflected by the body lumen wall 30 To the single mode fiber 2a8.
The light detection unit 2a5 detects the intensity of light obtained by combining the signal light L1 and the reference light L2.

図2のように光ファイバを用いた干渉計2aで構成された浸透度合い検出部2を用いた浸透性薬液20が浸透する度合いの検出は、次のようにして行う。
信号光L1と参照光L2の光路長が略等しくなったときのみ信号光L1と参照光L2が干渉しあい、信号光L1と参照光L2とが合波された光の干渉強度が大きくなる。屈折率の異なる界面で生じるすべてのフレネル反射光が信号光L1として存在するので、ミラー駆動部2a33を介してミラー2a32を光軸方向にある振幅を持って高速に振動させながら、光検出部2a5で信号光L1と参照光L2が合波された光の強度を検出すると、屈折率の異なる界面の位置に応じた複数の干渉波形が得られる。これは屈折率の断面プロファイルと等価である。
生体管腔内壁30の表面へ浸透性薬液20を噴霧した直後では、浸透性薬液20の表面でのフレネル反射光と浸透性薬液20と生体管腔内壁30の表面との界面でのフレネル反射光が信号光L1として存在するので、浸透度合い検出部2を用いると浸透性薬液20の光路長分を隔てて2つの干渉波形が得られることになる。
一定時間が経過し、浸透性薬液20の一部が生体管腔内壁30の表面から浸透し、かつ浸透性薬液20の一部が生体管腔内壁30の表面に残存している状態のときは、浸透性薬液20の表面でのフレネル反射光、浸透性薬液20と生体管腔内壁30の表面との界面でのフレネル反射光および浸透性薬液20が浸透した生体管腔内壁30の層と浸透性薬液20が浸透していない生体管腔内壁30の層との界面でのフレネル反射光が信号光L1として存在するので、浸透度合い検出部2を用いると浸透性薬液20の光路長分および浸透性薬液20が浸透した生体管腔内壁30の層の光路長分を隔てて3つの干渉波形が得られることになる。
さらに、浸透性薬液20の全部が生体管腔内壁30の表面から浸透した状態のときには、生体管腔内壁30の表面でのフレネル反射光と浸透性薬液20が浸透した生体管腔内壁30の層と浸透性薬液20が浸透していない生体管腔内壁30の層との界面でのフレネル反射光が信号光L1として存在するので、浸透度合い検出部2を用いると浸透性薬液20が浸透した生体管腔内壁30の層の光路長分を隔てて2つの干渉波形が得られることになる。
上記過程を、浸透度合い検出部2を用いてモニターすることで、生体管腔内壁30の内部組織への浸透度合いが所定の度合いに到達したものとして検出することができる。
The degree of penetration of the osmotic chemical solution 20 using the penetration degree detection unit 2 configured with an interferometer 2a using an optical fiber as shown in FIG. 2 is performed as follows.
Only when the optical path lengths of the signal light L1 and the reference light L2 are substantially equal, the signal light L1 and the reference light L2 interfere with each other, and the interference intensity of the light obtained by combining the signal light L1 and the reference light L2 increases. Since all the Fresnel reflection light generated at the interface having different refractive indexes exists as the signal light L1, the mirror 2a3 2 is vibrated at a high speed with an amplitude in the direction of the optical axis via the mirror driving unit 2a3 3, thereby detecting the light. When the intensity of the light obtained by combining the signal light L1 and the reference light L2 is detected by the unit 2a5, a plurality of interference waveforms corresponding to the positions of the interfaces having different refractive indexes are obtained. This is equivalent to a refractive index cross-sectional profile.
Immediately after spraying the osmotic chemical solution 20 onto the surface of the inner wall 30 of the living body lumen, Fresnel reflected light on the surface of the osmotic solution 20 and Fresnel reflected light at the interface between the osmotic solution 20 and the inner wall 30 of the living body lumen. Is present as the signal light L1, when the penetration degree detection unit 2 is used, two interference waveforms are obtained with an optical path length of the osmotic chemical solution 20 being separated.
When a certain period of time has elapsed, a part of the osmotic drug solution 20 penetrates from the surface of the living body lumen inner wall 30 and a part of the osmotic drug solution 20 remains on the surface of the living body lumen inner wall 30 The Fresnel reflected light on the surface of the osmotic chemical solution 20, the Fresnel reflected light on the interface between the osmotic chemical solution 20 and the surface of the inner wall 30 of the living body lumen, and the permeation through the layer of the inner wall 30 of the living body lumen into which the osmotic drug solution 20 has penetrated. Since the Fresnel reflected light at the interface with the layer of the inner wall 30 of the body lumen into which the sexual chemical solution 20 has not penetrated exists as the signal light L1, when the penetration degree detection unit 2 is used, the optical path length and penetration of the permeable chemical solution 20 Three interference waveforms are obtained by separating the optical path length of the layer of the inner wall 30 of the living body lumen into which the sexual drug solution 20 has permeated.
Further, when all of the osmotic chemical solution 20 has permeated from the surface of the inner wall 30 of the living body lumen, the layer of the inner wall 30 of the living body lumen 30 in which the Fresnel reflected light on the surface of the inner wall 30 of the living body lumen and the osmotic drug solution 20 have permeated. Since the Fresnel reflected light at the interface between the permeable drug solution 20 and the layer of the inner wall 30 of the living body lumen that has not penetrated exists as the signal light L1, when the penetration degree detection unit 2 is used, the osmotic drug solution 20 penetrates the living body. Two interference waveforms are obtained by separating the optical path length of the layer of the lumen inner wall 30.
By monitoring the above process using the permeation degree detection unit 2, it is possible to detect that the degree of permeation into the internal tissue of the inner wall 30 of the living body lumen has reached a predetermined degree.

なお、浸透度合い検出部2は、図2に示したような光ファイバを用いた干渉計2aからなる構成に限られるものではない。例えば、投与する浸透性薬液20が、生体管腔内壁30の表面に付着している体液に対し混ざらない性質を有している場合には、図3に示すような画像処理を介して浸透する度合いを検出するようにしてもよい。
図3の浸透度合い検出部2は、撮像部2b1と、画像処理部2b2と、鮮明度検出部2b3を有して構成されている。
撮像部2b1は、撮像光学系及び撮像素子で構成され、内視鏡の観察光学系4を経て所定の撮像位置に結像された生体管腔内壁30の表面の画像を撮像する。
画像処理部2b2は、図示しない内視鏡本体部に設けられており、撮像部2b1が撮像した生体管腔内壁30の表面の画像から、画像に写っている浸透性薬液20の液滴の輪郭形状を抽出するように構成されている。
鮮明度検出部2b3は、図示しない内視鏡本体部に設けられており、画像処理部2b2で抽出された浸透性薬液30の液滴の輪郭形状の鮮明度を、例えば、液滴の輪郭部分とその周囲とのコントラストに応じて数段階に検出するように構成されている。
そこで、図3のように構成された浸透度合い検出部2によれば、液滴の輪郭部分とその周囲とのコントラストが弱くなり、鮮明度が所定値以下となったときに、生体管腔内壁30の内部組織への浸透度合いが所定の度合いに到達したものとして検出することができる。
The penetration degree detection unit 2 is not limited to the configuration including the interferometer 2a using an optical fiber as shown in FIG. For example, in the case where the osmotic drug solution 20 to be administered has a property that it does not mix with the body fluid adhering to the surface of the inner wall 30 of the living body lumen, it penetrates through image processing as shown in FIG. The degree may be detected.
The penetration degree detection unit 2 in FIG. 3 includes an imaging unit 2b1, an image processing unit 2b2, and a sharpness detection unit 2b3.
The imaging unit 2b1 includes an imaging optical system and an imaging element, and captures an image of the surface of the inner wall 30 of the living body lumen formed at a predetermined imaging position via the observation optical system 4 of the endoscope.
The image processing unit 2b2 is provided in an endoscope main body (not shown), and from the image of the surface of the inner wall 30 of the living body lumen imaged by the imaging unit 2b1, the contour of the droplet of the osmotic drug solution 20 shown in the image It is configured to extract a shape.
The sharpness detection unit 2b3 is provided in an endoscope main body (not shown), and the sharpness of the contour shape of the droplet of the osmotic chemical solution 30 extracted by the image processing unit 2b2, for example, the contour portion of the droplet It is configured to detect in several stages according to the contrast between the image and its surroundings.
Therefore, according to the penetration degree detecting unit 2 configured as shown in FIG. 3, when the contrast between the contour portion of the droplet and its surroundings becomes weak and the sharpness becomes a predetermined value or less, the inner wall of the living body lumen It can be detected that the penetration degree of 30 internal tissues has reached a predetermined degree.

噴霧作動制御部3は、図示しない内視鏡本体部に設けられており、浸透度合い検出部2により検出された浸透性薬液20の生体管腔内壁30の内部組織への浸透する度合いが所定の度合いに到達したときに、薬液噴霧部1が浸透性薬液20を生体管腔内壁30の表面へ噴霧するように、薬液噴霧部1の作動を制御する。   The spray operation control unit 3 is provided in an endoscope main body (not shown), and has a predetermined degree of penetration of the osmotic drug solution 20 detected by the penetration degree detection unit 2 into the internal tissue of the living body lumen inner wall 30. When the degree is reached, the operation of the chemical spray unit 1 is controlled so that the chemical spray unit 1 sprays the osmotic chemical solution 20 onto the surface of the inner wall 30 of the living body lumen.

観察光学系4は、内視鏡先端部10に設けられており、図示しない接眼部又は図3に示したような撮像部2b1を介して生体管腔内壁30の画像を得ることができるように構成されている。   The observation optical system 4 is provided at the endoscope distal end 10 so that an image of the inner wall 30 of the living body lumen can be obtained via an eyepiece (not shown) or the imaging unit 2b1 as shown in FIG. It is configured.

状態変化検出部5は、図示しない内視鏡本体部に設けられており、内視鏡の観察光光学系4(更には図3に示したような撮像部2b1)を介して得られた生体管腔内壁30の画像から生体管腔内壁30の内部組織の状態変化を、例えば、画像に写っている生体管腔内壁30の透明度や色の変化に基づいて検出する。
また、噴霧作動制御部3は、さらに、状態変化検出部5により検出される生体管腔内壁30の内部組織の状態変化が所定状態に到達したとき、薬液噴霧部1による浸透性薬液20の生体管腔内壁30の表面への噴霧を終了させるように薬液噴霧部1の作動を制御する。
The state change detection unit 5 is provided in an endoscope main body (not shown), and a living body obtained through the observation light optical system 4 of the endoscope (further, the imaging unit 2b1 as shown in FIG. 3). A change in the state of the internal tissue of the biological lumen inner wall 30 is detected from the image of the lumen inner wall 30 based on, for example, a change in the transparency or color of the biological lumen inner wall 30 shown in the image.
Further, the spray operation control unit 3 further, when the state change of the internal tissue of the living body lumen inner wall 30 detected by the state change detection unit 5 reaches a predetermined state, the living body of the osmotic drug solution 20 by the drug solution spray unit 1. The operation of the chemical solution spray unit 1 is controlled so as to finish spraying on the surface of the lumen inner wall 30.

なお、本実施形態の浸透性薬液投与システムにおいては、図1(b)に示す噴霧作動制御部3の代わりに噴霧指示部3’を備えてもよい。
噴霧指示部3’は、浸透度合い検出部2により検出された浸透性薬液20の生体管腔内壁30の内部組織への浸透する度合いが所定の度合いに到達したときに、薬液噴霧部1による浸透性薬液20の生体管腔内壁30の表面への噴霧を指示するように構成される。
噴霧指示部3’における噴霧の指示は、例えば、図示しない内視鏡本体部に接続された表示装置の表示画面への噴霧指示メッセージの表示や、LEDを用いた光の点滅、音声発生機器を用いた音声の出力等、操作者の視覚や聴覚に対して刺激を与える手段を用いて構成するのが好ましい。
噴霧指示部3’を備えた構成の場合は、操作者は、噴霧指示部3から噴霧の指示を受ける都度、薬液噴霧部1による浸透性薬液20の生体管腔内壁30の表面への噴霧を手動で行う。
In addition, in the osmotic chemical | medical solution administration system of this embodiment, you may provide the spray instruction | indication part 3 'instead of the spray action control part 3 shown in FIG.1 (b).
The spray instructing unit 3 ′ penetrates the medicinal solution spray unit 1 when the degree of penetration of the osmotic chemical solution 20 detected by the penetration degree detecting unit 2 into the internal tissue of the inner wall 30 of the living body lumen reaches a predetermined level. It is configured to instruct spraying of the sex drug solution 20 onto the surface of the inner wall 30 of the living body lumen.
The spray instruction in the spray instructing unit 3 ′ is performed by, for example, displaying a spray instruction message on a display screen of a display device connected to an endoscope main body (not shown), blinking light using an LED, or a sound generating device. It is preferable to use a means for stimulating the visual and auditory senses of the operator, such as the output of the voice used.
In the case of the configuration including the spray instruction unit 3 ′, the operator sprays the surface of the inner wall 30 of the osmotic chemical solution 20 by the chemical solution spray unit 1 every time the spray instruction unit 3 receives a spray instruction. Do it manually.

このように構成された本実施形態の浸透性薬液投与システムを用いた投与対象部位(ここでは、生体管腔内壁30の患部30aの表面)への浸透性薬液の投与手順を、図4を用いて説明する。図4は、特に、生体組織への浸透よりも充分に長い時間および充分な量の薬液が必要な透明化液を投与する手順についての詳細が示されている。
まず、操作者は、内視鏡を生体管腔内壁30に挿入し、生体管腔内壁30に存在する患部30aを探す(ステップS1)。
患部30aの位置を確認した後、操作者は、内視鏡の鉗子チャネルから透明化液(浸透性薬液20)の噴霧デバイス(薬液噴霧部1)を挿入する(ステップS2)。
次いで、操作者は、噴霧デバイス1における透明化液20の供給口1bを患部30aに向ける(ステップS3)。
これにより、透明化液20を生体管腔内壁30の患部30aに投与する準備が完了する。
なお、浸透度合い検出部2を、図2に示した光ファイバを用いた干渉計2aで構成した場合、透明化液20の投与に先立ち、プローブ部2a4を患部30aに向けて、屈折率の断面プロファイルの取得を開始しておく。
The osmotic drug solution administration procedure to the administration target site (here, the surface of the affected part 30a of the living body lumen inner wall 30) using the osmotic drug solution administration system of the present embodiment configured as described above is shown in FIG. I will explain. FIG. 4 shows details of a procedure for administering a clearing solution that requires a sufficiently long time and a sufficient amount of drug solution, in particular, than the penetration into living tissue.
First, the operator inserts an endoscope into the inner wall 30 of the living body lumen and searches for an affected part 30a existing on the inner wall 30 of the living body lumen (step S1).
After confirming the position of the affected part 30a, the operator inserts a spraying device (medicine spraying part 1) of the clearing liquid (penetrating drug solution 20) from the forceps channel of the endoscope (step S2).
Next, the operator directs the supply port 1b of the clearing liquid 20 in the spray device 1 toward the affected part 30a (step S3).
Thereby, the preparation for administering the clarification solution 20 to the affected part 30a of the inner wall 30 of the living body lumen is completed.
When the penetration degree detecting unit 2 is configured by the interferometer 2a using the optical fiber shown in FIG. 2, prior to the administration of the clearing solution 20, the probe unit 2a4 is directed to the affected part 30a, and the refractive index cross section. Start acquiring the profile.

その後、透明化液20の生体管腔内壁30の患部30aへの投与を以下のステップS4〜S7に示す手順に従って行う。
患部30aを透明化するために必要な透明化液20の全投与量のうちの一部を患部30aの表面に噴霧する(ステップS4)。ここでは、この工程を第1の工程とする。ここで、透明化液20は上述したような組成および使用濃度から比較的粘性が高い場合が多いので、他の薬液と比べ生体組織表面に付着し易いといえるが、生体組織表面に粘液が存在したり、組織表層の微細構造等によっても付着量がばらつく可能性がある。そのため、浸透度合い検出部2は、対象となる部位における噴霧量を確認しながら、組織壁面への透明化液20の付着可能な許容量の最大となるような付着量を浸透度合いの下限値と設定し、噴霧動作中に下限値に達したときに噴霧量の停止を促す警告を発したり、噴霧動作を作動停止させるよう制御してもよい。
噴霧後、噴霧デバイス1による透明化液20の噴霧作動を停止させ、患部30aの内部組織への透明化液20の浸透する度合いが所定の度合いに到達するまで患部30aの表面への透明化液20の噴霧を待機させる(ステップS5、ステップS6)。ここでは、この工程を第2の工程とする。
内部組織への透明化液20の浸透する度合いが所定度合いに到達し、患部30aの内部組織の状態変化が所定状態に到達していないときは、ステップS4に示した第1の工程である、透明化液20の噴霧と、ステップ5に示した第2の工程である、患部30aの内部組織への透明化液20の浸透する度合いが所定の度合いに到達するまでの患部30aの表面への噴霧の待機とを繰り返す。一方、内部組織への透明化液20の浸透する度合いが所定度合いに到達し、患部30aの内部組織の状態変化が所定状態に到達したときに、透明化液20の噴霧を終了させる(ステップS7)。
これにより、患部30aの透明化に必要な全投与量の透明化液20が、例えば、図5に示すようなタイミングで、複数回に分けてロスなく投与されることになる。
Thereafter, the clearing solution 20 is administered to the affected part 30a of the inner wall 30 of the living body lumen according to the procedure shown in steps S4 to S7 below.
A part of the total dose of the clearing liquid 20 necessary to make the affected part 30a transparent is sprayed on the surface of the affected part 30a (step S4). Here, this step is defined as the first step. Here, since the clearing liquid 20 is often relatively viscous due to the composition and use concentration as described above, it can be said that the clearing liquid 20 easily adheres to the surface of a living tissue as compared with other chemicals, but mucus exists on the surface of the living tissue. Or the amount of adhesion may vary depending on the microstructure of the structure surface layer. Therefore, the permeation degree detection unit 2 sets the amount of adhesion that is the maximum permissible amount of the transparentizing liquid 20 to adhere to the tissue wall surface as the lower limit value of the permeation degree while confirming the spray amount at the target site. It may be set so that when the lower limit value is reached during the spraying operation, a warning for stopping the spray amount is issued, or the spraying operation is stopped.
After spraying, the spraying operation of the clearing liquid 20 by the spray device 1 is stopped, and the clearing liquid on the surface of the affected part 30a until the degree of penetration of the clearing liquid 20 into the internal tissue of the affected part 30a reaches a predetermined degree. 20 spraying is made to stand by (step S5, step S6). Here, this step is the second step.
When the degree of penetration of the clearing liquid 20 into the internal tissue reaches a predetermined level and the state change of the internal tissue of the affected part 30a has not reached the predetermined state, it is the first step shown in step S4. Spraying of the clearing liquid 20 and the second step shown in Step 5, the surface of the affected part 30 a until the degree of penetration of the clearing liquid 20 into the internal tissue of the affected part 30 a reaches a predetermined degree Repeat spraying and waiting. On the other hand, when the degree of penetration of the clarification liquid 20 into the internal tissue reaches a predetermined level and the state change of the internal tissue of the affected part 30a reaches a predetermined state, the spraying of the clarification liquid 20 is terminated (step S7). ).
Thereby, the clearing liquid 20 of the whole dose required for the clearing of the affected part 30a is administered, for example, at a timing as shown in FIG.

以下、鉗子チャネルから透明化液20の噴霧デバイス1を抜き出し(ステップS8)、手術を実施する(ステップS9)。   Thereafter, the spray device 1 of the clearing liquid 20 is extracted from the forceps channel (step S8), and the operation is performed (step S9).

本実施形態の浸透性薬液投与システムによれば、生体管腔内壁30に対する十分な効果を得るために必要な全投与量の浸透性薬液20を複数回に分けて少量ずつ霧状の液滴にして供給することができるので、浸透性薬液20の液滴が生体管腔内壁30の表面に留まり易くなる。そして、生体管腔内壁30における浸透性薬液20の投与対象部位(患部30a)が重力方向に反する位置に位置していても、噴霧した浸透性薬液20の液滴が重力方向に流れることなく、安定的に投与することができる。 According to osmotic drug solution administration system of the present embodiment, a sufficient effect on the total dose of permeable chemical liquid 20 necessary to obtain the small portions plural times atomized droplets against body lumen wall 30 Therefore, the droplet of the osmotic chemical solution 20 is likely to stay on the surface of the inner wall 30 of the living body lumen. And even if the administration target site (affected part 30a) of the osmotic drug solution 20 on the inner wall 30 of the living body lumen is located at a position opposite to the gravity direction, the sprayed droplets of the osmotic drug solution 20 do not flow in the gravity direction. It can be administered stably.

また、本実施形態の浸透性薬液投与システムによれば、浸透性薬液20を噴霧後に一定時間、噴霧を待機させることによって、生体管腔内壁30において重力方向に反する位置に位置する投与対象部位(患部30a)に噴霧した浸透性薬液20の液滴が大きくなって重力方向に流れることを防ぎ、浸透性薬液20を生体管腔内壁30の内部組織に浸透させることができる。 Further, according to the osmotic drug solution administration system of the present embodiment, the time constant permeability drug solution 20 after spraying, by waiting for spray administration subject site located at a position contrary to the direction of gravity in the body lumen wall 30 The droplets of the osmotic drug solution 20 sprayed on the (affected part 30a) can be prevented from becoming large and flowing in the direction of gravity, and the osmotic drug solution 20 can be infiltrated into the internal tissue of the living body lumen inner wall 30.

そして、本実施形態の浸透性薬液投与システムによれば、生体管腔内壁30において重力方向に反する位置に位置する投与対象部位(患部30a)に噴霧した浸透性薬液20の液滴が重力方向に流れることがない結果、生体管腔内壁30に対する十分な効果を得るために必要最小限となる最適量の浸透性薬液20を供給して、浸透性薬液20のロスを抑えることができるとともに、健康であって浸透性薬液20の投与が不必要な部位へ浸透性薬液20が投与されることを無くすことができ、健康な生体組織への負担を与えずに済む。 Then, according to the osmotic drug solution administration system of the present embodiment, droplets gravity direction of the administration target site penetration chemical 20 were sprayed (affected area 30a) located at a position contrary to the direction of gravity in the body lumen wall 30 As a result, it is possible to supply the optimal amount of the osmotic drug solution 20 that is necessary to obtain a sufficient effect on the inner wall 30 of the living body lumen, and to suppress the loss of the osmotic drug solution 20. It is possible to eliminate the administration of the osmotic drug solution 20 to a healthy site where the administration of the osmotic drug solution 20 is unnecessary, and it is not necessary to give a burden to a healthy living tissue.

また、本実施形態の浸透性薬液投与システムによれば、浸透性薬液20の投与を内視鏡先端部10の側方から浸透性薬液20を生体管腔内壁30の表面へ噴霧する薬液噴霧部1を介して行うので、例えば、薬液を徐放するためのバルーンを用いる構成や、WO2009/031295号公報に記載の薬剤徐放性ステントのように、薬液の投与部位の視野を妨げない。このため、生体管腔内壁30における投与部位(患部30a)での効果を確認しながら浸透性薬液20を投与することができる。   In addition, according to the osmotic drug solution administration system of the present embodiment, the drug solution spraying unit sprays the osmotic drug solution 20 onto the surface of the inner wall 30 of the living body lumen from the side of the endoscope distal end 10. Therefore, the visual field of the administration site of the drug solution is not hindered, for example, as in the configuration using a balloon for sustained release of the drug solution and the drug sustained release stent described in WO2009 / 031295. For this reason, the osmotic drug solution 20 can be administered while confirming the effect at the administration site (affected part 30a) in the inner wall 30 of the living body lumen.

従って、本実施形態の浸透性薬液投与システムによれば、生体への負担及び作業負担を軽減し、薬液のロスを極力省くことができ、重力に反する位置に存在する投与対象部位に対しても薬液を安定的に留置させた状態で、最適な量を調整することが可能で、しかも投与部位の視野を邪魔せず、薬液の投与効果を確認しながら投与することが可能な浸透性薬液投与システムが得られる。 Therefore, according to the osmotic drug solution administration system of the present embodiment, to reduce the burden and work load on the living body, it is possible to omit the loss of the chemical as possible with respect to the administration subject site present in position against the force of gravity However, it is possible to adjust the optimal amount in a state where the drug solution is stably placed, and the osmotic drug solution can be administered while checking the effect of the drug solution without interfering with the visual field of the administration site. administration system is obtained.

また、本実施形態の浸透性薬液投与システムにおいて、図1(b)に示したように、浸透度合い検出部2により検出された浸透性薬液20の生体管腔内壁30の内部組織への浸透する度合いが所定の度合いに到達したときに、薬液噴霧部1が浸透性薬液20を生体管腔内壁30の表面へ噴霧するように、薬液噴霧部1の作動を制御する噴霧作動制御部3を有すれば、薬液噴霧部1を介して浸透性薬液20を噴霧するのに最適なタイミングを簡単に取得して、最適なタイミングで浸透性薬液20を自動的に噴霧させることができ、操作者による噴霧指示の確認や薬液噴霧部1の作動を手動で操作する手間を省いて、操作者の作業負担を軽減することができる。   Further, in the osmotic drug solution administration system of the present embodiment, as shown in FIG. 1B, the osmotic drug solution 20 detected by the penetration level detection unit 2 penetrates into the internal tissue of the inner wall 30 of the living body lumen. When the degree reaches a predetermined degree, a spray operation control unit 3 that controls the operation of the chemical spray unit 1 is provided so that the chemical spray unit 1 sprays the osmotic chemical solution 20 onto the surface of the inner wall 30 of the living body lumen. Then, the optimal timing for spraying the osmotic chemical solution 20 via the chemical spray unit 1 can be easily obtained, and the osmotic drug solution 20 can be automatically sprayed at the optimal timing. It is possible to reduce the burden on the operator by eliminating the trouble of manually operating the operation of the spraying unit 1 and the confirmation of the spraying instruction.

また、本実施形態の浸透性薬液投与システムにおいて、浸透度合い検出部2により検出された浸透性薬液20の生体管腔内壁30の内部組織への浸透する度合いが所定の度合いに到達したときに、薬液噴霧部1による浸透性薬液20の生体管腔内壁30の表面への噴霧を指示する噴霧指示部3’を有すれば、操作者による噴霧指示の確認の手間を省いて、操作者の作業負担を軽減することができる。   Further, in the osmotic drug solution administration system of the present embodiment, when the penetration level of the osmotic drug solution 20 detected by the penetration level detection unit 2 into the internal tissue of the inner wall 30 of the living body lumen reaches a predetermined level, If the spray instructing unit 3 ′ for instructing spraying of the osmotic chemical solution 20 onto the surface of the inner wall 30 of the living body lumen by the medicinal solution spraying unit 1 is provided, the operator's work can be saved without having to confirm the spray instruction by the operator. The burden can be reduced.

また、本実施形態の浸透性薬液投与システムにおいて、浸透度合い検出部2を、図2に示したように、光ファイバを用いた干渉計2aで構成すれば、噴霧した浸透性薬液20の液滴が生体管腔内壁30の表面の体液と混ざって、観察画像からは浸透性薬液20が生体管腔内壁30の内部組織への浸透の度合いが判別しにくくなるような場合であっても、浸透性薬液20と生体管腔内壁30の表面及び生体管腔内壁30の表面に付着する体液との夫々の屈折率の差異に基づく信号光の光路長の変化を、信号光と参照光との合波された光の強度の違いとして区別することができるため、浸透性薬液20が生体管腔内壁30の内部組織へ浸透する度合いを正確に検出することができる。   Moreover, in the osmotic chemical solution administration system of the present embodiment, if the penetration degree detection unit 2 is configured by an interferometer 2a using an optical fiber as shown in FIG. Is mixed with the body fluid on the surface of the inner wall 30 of the living body lumen, and the permeation of the osmotic drug solution 20 from the observation image becomes difficult to determine the degree of penetration into the internal tissue of the inner wall 30 of the living body lumen. The change in the optical path length of the signal light based on the difference in refractive index between the sex drug solution 20 and the surface of the living body lumen inner wall 30 and the body fluid adhering to the surface of the living body lumen inner wall 30 is obtained by combining the signal light and the reference light. Since it can be distinguished as the difference in intensity of the waved light, the degree of penetration of the osmotic chemical solution 20 into the internal tissue of the inner wall 30 of the living body lumen can be accurately detected.

また、本実施形態の浸透性薬液投与システムにおいて、浸透度合い検出部2を、図3に示したように、内視鏡の観察光学系4を介して得られた生体管腔内壁30の表面の画像を撮像する撮像部2b1と、撮像部2b1が撮像した生体管腔内壁30の表面の画像における噴霧された浸透性薬液20の液滴の輪郭形状を抽出する画像処理部2b2と、画像処理部2b2で抽出された浸透性薬液の液滴の輪郭形状の鮮明度を検出する鮮明度検出部2b3を有して構成すれば、内視鏡先端部10に浸透度合いを検出するための部材を新たに設ける必要がない。このため、内視鏡先端部10を極力小さく抑えることができ、径の小さな生体管腔内壁30に対しても浸透性薬液10の浸透の度合いを検出することができるようになる。   Further, in the osmotic drug solution administration system of the present embodiment, as shown in FIG. 3, the penetration degree detection unit 2 is provided on the surface of the inner wall 30 of the living body lumen obtained through the observation optical system 4 of the endoscope. An image capturing unit 2b1 that captures an image, an image processing unit 2b2 that extracts a contour shape of a droplet of the sprayed osmotic chemical solution 20 in an image of the surface of the inner wall 30 of the living body lumen captured by the image capturing unit 2b1, and an image processing unit If the sharpness detection unit 2b3 that detects the sharpness of the contour shape of the osmotic chemical liquid droplet extracted in 2b2 is provided, a member for detecting the penetration degree is newly added to the endoscope distal end portion 10. There is no need to provide it. For this reason, the endoscope front-end | tip part 10 can be restrained as much as possible, and the penetration | invasion degree of the permeable chemical | medical solution 10 can be detected now also with respect to the biological lumen inner wall 30 with a small diameter.

また、本実施形態の浸透性薬液投与システムにおいて、さらに、図1(b)に示すように、内視鏡の観察光学系4を介して得られた生体管腔内壁30の画像から生体管腔内壁30の内部組織の状態変化を検出する状態変化検出部5を有し、噴霧作動制御部3を、状態変化検出部5により検出される生体管腔内壁30の内部組織の状態変化が所定状態に到達したときに、薬液噴霧部1による浸透性薬液20の生体管腔内壁30の表面への噴霧を終了させるように、薬液噴霧部1の作動を制御するように構成すれば、操作者の作業負担を減らしながら、過剰投与を防止して最適な量の浸透性薬液を生体管腔内壁30に投与することができる。   Further, in the osmotic drug solution administration system of the present embodiment, as shown in FIG. 1 (b), the living body lumen is obtained from the image of the inner wall 30 of the living body lumen obtained through the observation optical system 4 of the endoscope. The state change detection unit 5 that detects the state change of the internal tissue of the inner wall 30 has a predetermined state in which the state change of the internal tissue of the living body lumen inner wall 30 detected by the state change detection unit 5 If the operation of the drug solution spraying unit 1 is controlled so that the spraying of the osmotic drug solution 20 onto the surface of the inner wall 30 of the living body lumen by the drug solution spraying unit 1 is terminated, the operator's It is possible to administer an optimal amount of the osmotic drug solution to the inner wall 30 of the living body lumen while reducing the work load while preventing excessive administration.

以上、本発明の浸透性薬液投与システムの実施形態を説明したが、本発明の浸透性薬液投与システムは、上記実施形態の構成に限定されるものではない。
例えば、本発明において、「内視鏡」という語は、浸透性薬剤の浸透状態を検出するための手段を有する場合には、カテーテルのような観察目的ではない体内用処置具に対しディスプレイ上に観察可能な浸透状態に関する分布データを表示する場合を含む広義なものである。
また、第2の工程において、薬液噴霧部1による浸透性薬液20の噴霧を完全に停止するのではなく、第1の工程に比べて微量の浸透性薬液20を噴霧するように、噴霧量を工程ごとに調整できるように、噴霧作動制御部3を構成してもよい。
また、状態変化検出部5としては、上述した例に限らず、生体組織表面の状態が、浸透性薬液20の有無や噴霧による付着量に応じて異なる状態であることを認識する手段であれば、他の手段(例えば、液面検出用超音波センサー、インピーダンス測定用電極)であってもよい。
また、状態変化検出部5が検出した生体管腔内壁30の内部組織の状態変化に応じて、薬液噴霧部1による浸透性薬液20の噴霧量を調整できるように、噴霧作動制御部3を構成してもよい。
また、所定量の浸透性薬液20の噴霧に対する生体管腔内壁30の内部組織への浸透時間がおおよそ判明している場合には、浸透度合い検出部2をタイマーで構成し、所定時間経過ごとに浸透性薬液1を噴霧することができるようにしてもよい。
また、本発明の浸透性薬液投与システムに用いる浸透性薬液は、透明化液である場合が最も効果的であるが、生体組織に対し浸透性と薬効を有する薬液であれば、染色液、造影剤であってもよく、さらには、患部を透明化した後に元の不透明な状態に戻す際に用いられるリン酸緩衝生理食塩水(PBS)等の復元用溶液であってもよい。
Having described the embodiments of the osmotic drug solution administration system of the present invention, permeable chemical liquid administration system of the present invention is not limited to the configuration of the above embodiment.
For example, in the present invention, the term “endoscope” is used on a display for a treatment instrument for internal use that is not an observation purpose such as a catheter when it has a means for detecting the penetration state of a penetrating drug. This is a broad sense including the case of displaying distribution data relating to the observable penetration state.
Further, in the second step, the spray amount is set not to completely stop the spraying of the osmotic chemical solution 20 by the chemical spray unit 1 but to spray a small amount of the osmotic chemical solution 20 compared to the first step. You may comprise the spray action control part 3 so that it can adjust for every process.
In addition, the state change detection unit 5 is not limited to the above-described example, and may be any means that recognizes that the state of the surface of the living tissue is in a different state depending on the presence or absence of the osmotic chemical solution 20 or the amount of adhesion by spraying. Other means (for example, an ultrasonic sensor for detecting a liquid level, an electrode for impedance measurement) may be used.
Further, the spray operation control unit 3 is configured so that the spray amount of the osmotic chemical solution 20 by the chemical solution spray unit 1 can be adjusted according to the state change of the internal tissue of the inner wall 30 of the living body lumen detected by the state change detection unit 5. May be.
Further, when the penetration time into the internal tissue of the living body lumen inner wall 30 with respect to the spraying of the predetermined amount of the osmotic chemical solution 20 is roughly known, the penetration degree detection unit 2 is configured by a timer, and every predetermined time has elapsed. The osmotic chemical solution 1 may be sprayed.
Further, permeable chemical liquid used in the osmotic drug solution administration system of the present invention is when a transparent solution is the most effective, as long as the drug solution having a permeability and efficacy to the living tissue, staining solution, It may be a contrast medium, or may be a restoration solution such as phosphate buffered saline (PBS) used when the affected area is made transparent and then returned to the original opaque state.

本発明の浸透性薬液投与システムは、重力に反した方向に存在する患部に、透明化液などの浸透性薬液を投与し、投与後に患部を診断又は治療することが必要とされるあらゆる分野に有用である。 Permeable chemical liquid administration system of the present invention, all areas in the affected area that exists in a direction against gravity, administered permeability chemical such as transparency solution, it is required to diagnose or treat the affected area after administration Useful for.

1 薬液噴霧部
1a 供給路
1b 供給口
2 浸透度合い検出部
2a 光ファイバを用いた干渉計
2a1 光源部
2a2 ファイバカプラ
2a3 参照光反射系
2a31 レンズ
2a32 ミラー
2a33 ミラー駆動部
2a4 プローブ部
2a41 レンズ
2a5 光検出部
2a6、2a7、2a8、2a9 シングルモードファイバ
2b1 撮像部
2b2 画像処理部
2b3 鮮明度検出部
3 噴霧作動制御部
3’ 噴霧指示部
4 観察光学系
5 状態変化検出部
10 内視鏡先端部
11 可撓性部材
20 浸透性薬液
30 生体管腔内壁
30a 患部
DESCRIPTION OF SYMBOLS 1 Chemical spray part 1a Supply path 1b Supply port 2 Penetration degree detection part 2a Interferometer 2a1 using optical fiber Light source part 2a2 Fiber coupler 2a3 Reference light reflection system 2a3 1 Lens 2a3 2 Mirror 2a3 3 Mirror drive part 2a4 Probe part 2a4 1 Lens 2a5 Light detection unit 2a6, 2a7, 2a8, 2a9 Single mode fiber 2b1 Imaging unit 2b2 Image processing unit 2b3 Sharpness detection unit 3 Spray operation control unit 3 'Spray instruction unit 4 Observation optical system 5 State change detection unit 10 Endoscope Tip 11 Flexible member 20 Osmotic drug solution 30 Body lumen inner wall 30a Affected part

Claims (6)

内視鏡を用いて浸透性薬液を生体管腔内壁へ投与する浸透性薬液投与システムであって、
前記内視鏡先端部の側方から前記浸透性薬液を前記生体管腔内壁の表面へ噴霧可能に構成された薬液噴霧部と、
前記薬液噴霧部により前記生体管腔内壁の表面へ噴霧された前記浸透性薬液が該生体管腔内壁の内部組織へ浸透する度合いを検出する浸透度合い検出部を有し、
前記薬液噴霧部が前記浸透性薬液を前記生体管腔内壁の表面へ噴霧する第1の工程と、前記第1の工程の後に前記浸透度合い検出部により検出された前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達するまでの間、前記薬液噴霧部による前記浸透性薬液の前記生体管腔内壁の表面への噴霧を待機させる第2の工程とを交互に繰り返し、前記生体管腔内壁に対し所定量の前記浸透性薬液を複数回に分けて断続的に投与するようにしたことを特徴とする浸透性薬液投与システム。
An osmotic drug solution administration system for administering an osmotic drug solution to an inner wall of a living body lumen using an endoscope,
A medicinal solution spraying part configured to be able to spray the penetrating medicinal solution on the surface of the inner wall of the living body lumen from the side of the endoscope distal end part;
An infiltration degree detection unit for detecting the degree of penetration of the osmotic chemical solution sprayed onto the surface of the inner wall of the biological lumen by the medicinal solution spraying unit;
A first step of spraying the osmotic chemical solution onto the surface of the inner wall of the living body lumen by the medicinal solution spraying unit; and the biological tube of the osmotic drug solution detected by the permeation degree detecting unit after the first step. A second step of waiting for spraying of the osmotic chemical liquid onto the surface of the inner wall of the living body lumen by the chemical liquid spraying section until the degree of penetration into the internal tissue of the lumen inner wall reaches a predetermined level; An osmotic drug solution administration system, which is alternately repeated, and a predetermined amount of the osmotic drug solution is intermittently administered to the inner wall of the living body lumen in a plurality of times.
さらに、前記浸透度合い検出部により検出された前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達したときに、前記薬液噴霧部が前記浸透性薬液を前記生体管腔内壁の表面へ噴霧するように、前記薬液噴霧部の作動を制御する噴霧作動制御部を有することを特徴とする請求項1に記載の薬液投与システム。   Furthermore, when the degree of penetration of the osmotic drug solution detected by the penetration degree detection unit into the internal tissue of the inner wall of the living body lumen reaches a predetermined level, the drug solution spraying unit transfers the osmotic drug solution to the The medicinal-solution administration system according to claim 1, further comprising a nebulization operation control unit that controls the operation of the medicinal-solution spraying unit so as to spray onto the surface of the inner wall of the living body lumen. さらに、前記浸透度合い検出部により検出された前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いが所定の度合いに到達したときに、前記薬液噴霧部による前記浸透性薬液の前記生体管腔内壁の表面への噴霧を指示する噴霧指示部を有することを特徴とする請求項1に記載の薬液投与システム。   Further, when the degree of penetration of the osmotic drug solution detected by the penetration level detection unit into the internal tissue of the inner wall of the living body lumen reaches a predetermined level, the osmotic drug solution by the drug solution spray unit is The medicinal-solution administration system according to claim 1, further comprising a spray instructing unit that instructs spraying on a surface of the inner wall of a living body lumen. 前記浸透度合い検出部が、光ファイバを用いた干渉計からなることを特徴とする請求項1〜3のいずれかに記載の薬液投与システム。   The medicinal solution administration system according to any one of claims 1 to 3, wherein the permeation degree detection unit includes an interferometer using an optical fiber. 前記浸透度合い検出部が、前記内視鏡の観察光学系を介して得られた前記生体管腔内壁の表面の画像を撮像する撮像部と、前記撮像部が撮像した前記生体管腔内壁の表面の画像から、該画像に写っている前記浸透性薬液の液滴の輪郭形状を抽出する画像処理部と、前記画像処理部で抽出された前記浸透性薬液の液滴の輪郭形状の鮮明度を検出する鮮明度検出部を有してなり、
前記鮮明度検出部により検出された前記鮮明度が、前記浸透性薬液の前記生体管腔内壁の内部組織への浸透する度合いであることを特徴とする請求項1〜3のいずれかに記載の薬液投与システム。
The penetration degree detecting unit picks up an image of the surface of the inner wall of the living body lumen obtained through the observation optical system of the endoscope, and the surface of the inner wall of the living body lumen taken by the imaging unit The image processing unit for extracting the contour shape of the droplet of the osmotic chemical solution reflected in the image, and the definition of the contour shape of the droplet of the osmotic chemical solution extracted by the image processing unit. It has a sharpness detection part to detect,
4. The sharpness detected by the sharpness detection unit is a degree of penetration of the osmotic chemical solution into an internal tissue of the inner wall of the living body lumen. Chemical solution administration system.
さらに、前記内視鏡の観察光学系を介して得られた前記生体管腔内壁の画像から前記生体管腔内壁の内部組織の状態変化を検出する状態変化検出部を有し、
前記噴霧作動制御部は、前記状態変化検出部により検出される前記生体管腔内壁の内部組織の状態変化が所定状態に到達したときに、前記薬液噴霧部による前記浸透性薬液の前記生体管腔内壁の表面への噴霧を終了させるように、前記薬液噴霧部の作動を制御することを特徴とする請求項2、請求項2に従属する請求項4又は5のいずれかに記載の薬液投与システム。
And a state change detection unit that detects a state change of the internal tissue of the inner wall of the living body lumen from an image of the inner wall of the living body lumen obtained through the observation optical system of the endoscope,
When the state change of the internal tissue of the inner wall of the living body lumen detected by the state change detecting unit reaches a predetermined state, the spray operation control unit is configured so that the living body lumen of the osmotic drug solution by the drug solution spraying unit is 6. The medicinal solution administration system according to claim 2, wherein operation of the medicinal solution spraying unit is controlled so as to finish spraying on the surface of the inner wall. .
JP2013153493A 2013-07-24 2013-07-24 Osmotic chemical administration system Expired - Fee Related JP6192407B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013153493A JP6192407B2 (en) 2013-07-24 2013-07-24 Osmotic chemical administration system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013153493A JP6192407B2 (en) 2013-07-24 2013-07-24 Osmotic chemical administration system

Publications (2)

Publication Number Publication Date
JP2015023904A JP2015023904A (en) 2015-02-05
JP6192407B2 true JP6192407B2 (en) 2017-09-06

Family

ID=52489126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013153493A Expired - Fee Related JP6192407B2 (en) 2013-07-24 2013-07-24 Osmotic chemical administration system

Country Status (1)

Country Link
JP (1) JP6192407B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10857020B2 (en) 2017-09-14 2020-12-08 Olympus Corporation Gastrointestinal track constricting method
US10561489B2 (en) 2018-03-05 2020-02-18 Olympus Corporation Gastrointestinal-tract constricting method
US10555801B2 (en) 2018-03-05 2020-02-11 Olympus Corporation Gastrointestinal-tract constricting method
US10918454B2 (en) 2018-04-02 2021-02-16 Olympus Corporation Gastrointestinal tract constricting method
EP3974438A4 (en) 2019-05-21 2023-05-10 The University of Tokyo Fluorescent probe for use in detection of brain tumor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568027A (en) * 1979-07-03 1981-01-27 Olympus Optical Co Anesthesia apparatus for endoscope
JPH03207335A (en) * 1990-01-09 1991-09-10 Hoya Corp Endoscope
JP3191717B2 (en) * 1991-11-05 2001-07-23 セイコーエプソン株式会社 Micro robot
JP4716922B2 (en) * 2006-05-23 2011-07-06 オリンパスメディカルシステムズ株式会社 Capsule type medical device and drug introduction system using the same
WO2009023798A2 (en) * 2007-08-14 2009-02-19 Fred Hutchinson Cancer Research Center Needle array assembly and method for delivering therapeutic agents
JP4810623B2 (en) * 2009-08-07 2011-11-09 オリンパスメディカルシステムズ株式会社 Medical system

Also Published As

Publication number Publication date
JP2015023904A (en) 2015-02-05

Similar Documents

Publication Publication Date Title
JP6192407B2 (en) Osmotic chemical administration system
JP6608434B2 (en) Method and apparatus for detecting the position between layers of the eye
US20150313633A1 (en) Pericardial access device
US8903476B2 (en) Multi-function optical probe system for medical and veterinary applications
JP4747321B2 (en) Ileus tube type small intestine endoscope that can be laser-examined and treated
US20150313634A1 (en) Pericardial access device
JP2012504019A5 (en)
US20070142714A1 (en) Precision sensing and treatment delivery device for promoting healing in living tissue
US20100081873A1 (en) Systems and methods for optical viewing and therapeutic intervention in blood vessels
JP2013509245A (en) Ocular treatment device and method
WO2014183123A1 (en) Oct vitrectomy probe
WO2022199161A1 (en) Thoracoscopic treatment system for heart failure
JP2019513441A (en) Apparatus for ultrasonically accelerating hemolysis or thrombolysis of hemorrhage or hematoma in the brain or intracerebroventricular
WO2016042641A1 (en) Administration system for permeable liquid medicine and administration method for permeable liquid medicine
JP7223176B2 (en) Method and apparatus for scanning blood vessels
US10806903B2 (en) Handheld multi-needle vascular access device
JP2014161384A (en) Liquid sustained release means, and endoscope and endoscope surgical instrument including the same
JP2021500198A (en) Ophthalmic microsurgical instrument
NL2019493B1 (en) Imaging device
JP2021527488A (en) Drug delivery system and method for treating the nasal cavity
JP2015126885A (en) Medical instrument emitting near infrared fluorescence and medical instrument position confirmation system
RU2702440C2 (en) Device for treating haemorrhoids with continuous doppler control
JPH04131746A (en) Laser diagnostic device
KR102482018B1 (en) Non invasive Vascular Angiography device
JP2012050513A (en) Endoscopic hood

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170131

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170808

R151 Written notification of patent or utility model registration

Ref document number: 6192407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

LAPS Cancellation because of no payment of annual fees